Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease.

Basi GS, Feinberg H, Oshidari F, Anderson J, Barbour R, Baker J, Comery TA, Diep L, Gill D, Johnson-Wood K, Goel A, Grantcharova K, Lee M, Li J, Partridge A, Griswold-Prenner I, Piot N, Walker D, Widom A, Pangalos MN, Seubert P, Jacobsen JS, Schenk D, Weis WI.

J Biol Chem. 2010 Jan 29;285(5):3417-27. doi: 10.1074/jbc.M109.045187. Epub 2009 Nov 18.

2.

Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse.

Seubert P, Barbour R, Khan K, Motter R, Tang P, Kholodenko D, Kling K, Schenk D, Johnson-Wood K, Schroeter S, Gill D, Jacobsen JS, Pangalos M, Basi G, Games D.

Neurodegener Dis. 2008;5(2):65-71. doi: 10.1159/000112834. Epub 2008 Jan 4.

PMID:
18182780
3.

Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice.

McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S.

J Biol Chem. 2007 Sep 7;282(36):26326-34. Epub 2007 Jul 6.

4.

Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease.

Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D.

J Neurosci. 2005 Oct 5;25(40):9096-101.

5.

Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.

Lee M, Bard F, Johnson-Wood K, Lee C, Hu K, Griffith SG, Black RS, Schenk D, Seubert P.

Ann Neurol. 2005 Sep;58(3):430-5.

PMID:
16130106
6.

Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 3. Erratum in: Proc Natl Acad Sci U S A. 2004 Aug 3;101(3):11526.

7.

Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice.

Brayden DJ, Templeton L, McClean S, Barbour R, Huang J, Nguyen M, Ahern D, Motter R, Johnson-Wood K, Vasquez N, Schenk D, Seubert P.

Vaccine. 2001 Jul 20;19(30):4185-93.

PMID:
11457544
8.

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.

Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L.

Hum Mol Genet. 2001 Jun 1;10(12):1317-24.

PMID:
11406613
9.

Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.

Games D, Bard F, Grajeda H, Guido T, Khan K, Soriano F, Vasquez N, Wehner N, Johnson-Wood K, Yednock T, Seubert P, Schenk D.

Ann N Y Acad Sci. 2000;920:274-84.

PMID:
11193164
10.

Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.

Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ, Hu KL, Johnson-Wood KL, Kennedy SL, Kholodenko D, Knops JE, Latimer LH, Lee M, Liao Z, Lieberburg IM, Motter RN, Mutter LC, Nietz J, Quinn KP, Sacchi KL, Seubert PA, Shopp GM, Thorsett ED, Tung JS, Wu J, Yang S, Yin CT, Schenk DB, May PC, Altstiel LD, Bender MH, Boggs LN, Britton TC, Clemens JC, Czilli DL, Dieckman-McGinty DK, Droste JJ, Fuson KS, Gitter BD, Hyslop PA, Johnstone EM, Li WY, Little SP, Mabry TE, Miller FD, Audia JE.

J Neurochem. 2001 Jan;76(1):173-81.

11.

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease.

Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T.

Nat Med. 2000 Aug;6(8):916-9.

PMID:
10932230
12.

High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L.

J Neurosci. 2000 Jun 1;20(11):4050-8.

13.

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P.

Nature. 1999 Jul 8;400(6740):173-7.

PMID:
10408445
14.

Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease.

Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L.

Nature. 1997 Oct 9;389(6651):603-6.

PMID:
9335500
15.

Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L.

Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1550-5.

16.

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice.

Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ.

Nat Med. 1997 Jan;3(1):67-72.

PMID:
8986743
17.

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Green R, et al.

Ann Neurol. 1995 Oct;38(4):643-8.

PMID:
7574461
18.

Identification of secreted beta-amyloid precursor protein binding sites on intact human fibroblasts.

Johnson-Wood KL, Henriksson T, Seubert P, Oltersdorf T, Lieberburg I, Schenk DB.

Biochem Biophys Res Commun. 1994 May 16;200(3):1685-92.

PMID:
8185626
19.

Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.

Knops J, Johnson-Wood K, Schenk DB, Sinha S, Lieberburg I, McConlogue L.

J Biol Chem. 1991 Apr 15;266(11):7285-90.

20.

Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay.

Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson-Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, et al.

J Neurochem. 1991 Mar;56(3):1037-42.

PMID:
1899691
21.

The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II.

Oltersdorf T, Fritz LC, Schenk DB, Lieberburg I, Johnson-Wood KL, Beattie EC, Ward PJ, Blacher RW, Dovey HF, Sinha S.

Nature. 1989 Sep 14;341(6238):144-7.

PMID:
2506449

Supplemental Content

Loading ...
Support Center